News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Yao-Yu Wu, MD

Articles by Yao-Yu Wu, MD

Although surgery and radiotherapy are standard treatments for localized STS, the role of adjuvant chemotherapy, particularly doxorubicin, in high-grade STS is debated.

Single-Agent Doxorubicin Adjuvant Chemotherapy for Resectable Grade 2/3 Soft Tissue Sarcomas: A Retrospective Study

ByShiny Chih-Hsuan Wu, MD,Yao-Yu Wu, MD,Chi-Ting Liau, MD,Chih‑Hsiang Chang, MD,Shih-Chiang Huang, MD,Hsin‑Nung Shih, MD,Chun-Chieh Chen, MD, PhD

March 26th 2026

Latest Updated Articles

Single-Agent Doxorubicin Adjuvant Chemotherapy for Resectable Grade 2/3 Soft Tissue Sarcomas: A Retrospective Study
March 26th 2026

Trending on CancerNetwork

Where Does LAG-3/PD-1 Inhibition Fit In PD-1–Refractory Hodgkin Lymphoma?

Sigvotatug Vedotin Does Not Significantly Improve Survival in NSCLC Trial

Cellular Therapy and Antibody-Drug Conjugates Shape Day 1 of ASCO Breakthrough 2026

Offering Hope and Support Toward the Cancer Survivorship Journey

Generic Enzalutamide Receives Tentative FDA Approval in Prostate Cancer